Unbiased Analysis of Today's Healthcare Issues
That is the title of a new USC white paper by Darren Filson, Karen Van Nuys, Darius Lakdawalla and Dana Goldman with the subtitle “How Much Does Revenue Drive New Drug Development?” What is the elasticity of innovation? It measures the percentage change in innovation—using the flow of new drugs approvals, or Phase 1, 2,…
This is a common question I receive, often with the implicit assumption that prices in the US are too high. One key question to consider is, what are we trying to optimize? Tyler Cowen has a very good and brief post talking about drug prices and makes the case that (i) the supply of new…
It stands to reason that policies that aim to reduce drug prices or squeeze life science companies profits are likely to decrease incentives to finance the research and development needed to bring a drug to market. Previous estimates claim that bringing a new drug to market may cost over $2 billion, and life science companies…